Which drug is a direct-acting muscarinic agonist commonly used to treat xerostomia (dry mouth)?

Which drug is a direct-acting muscarinic agonist commonly used to treat xerostomia (dry mouth)?

• A. Pilocarpine
• B. Methacholine
• C. Varenicline
• D. Demecarium

Answer: (A)

Activating muscarinic receptors on salivary glands increases saliva production, so a drug that directly stimulates these receptors is best for treating dry mouth. Pilocarpine fits this role perfectly because it directly binds and activates muscarinic receptors, especially in the salivary glands, leading to more saliva and relief from xerostomia. Other options don’t fit as well. Methacholine is primarily used in bronchial challenge testing and mainly affects the airways, not mainly for saliva. Varenicline acts on nicotinic receptors and is used for smoking cessation, not to stimulate saliva. Demecarium is an acetylcholinesterase inhibitor, which increases acetylcholine levels indirectly rather than directly activating muscarinic receptors. So, the direct-acting muscarinic agonist used to treat xerostomia is pilocarpine.

Activating muscarinic receptors on salivary glands increases saliva production, so a drug that directly stimulates these receptors is best for treating dry mouth. Pilocarpine fits this role perfectly because it directly binds and activates muscarinic receptors, especially in the salivary glands, leading to more saliva and relief from xerostomia.

Other options don’t fit as well. Methacholine is primarily used in bronchial challenge testing and mainly affects the airways, not mainly for saliva. Varenicline acts on nicotinic receptors and is used for smoking cessation, not to stimulate saliva. Demecarium is an acetylcholinesterase inhibitor, which increases acetylcholine levels indirectly rather than directly activating muscarinic receptors.

So, the direct-acting muscarinic agonist used to treat xerostomia is pilocarpine.